BioNTech SE (BNTX) Total Non-Current Liabilities (2018 - 2025)

BioNTech SE has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $724.2 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $724.2 million, up 13.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $724.2 million (up 13.82% YoY), and the FY2025 annual result was $702.9 million, up 10.47% from the prior year.
• Total Non-Current Liabilities came in at $724.2 million for Q4 2025 at BioNTech SE, down from $749.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 billion in Q2 2025 to a low of $278.4 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $620.8 million (2021), against an average of $639.9 million.
• Across the five-year window, Total Non-Current Liabilities surged 237.3% in 2021 and tumbled 53.47% in 2022, its largest moves.
• BioNTech SE's Total Non-Current Liabilities stood at $521.1 million in 2021, then slumped by 46.57% to $278.4 million in 2022, then surged by 166.6% to $742.3 million in 2023, then slipped by 14.29% to $636.2 million in 2024, then grew by 13.82% to $724.2 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $724.2 million (Q4 2025), $749.7 million (Q3 2025), and $1.5 billion (Q2 2025), per Business Quant data.